Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
RedChip Companies will air interviews with Nexalin Technology (Nasdaq:NXL) and VolitionRX (NYSE American:VNRX) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, June 15, at 7 p.m. ET. Nexalin's CEO, Mark White, discusses their non-invasive neurostimulation technology for mental health conditions like insomnia, PTSD, and traumatic brain injuries. Volition's CEO, Cameron Reynolds, highlights their epigenetic markers for diagnostics, focusing on cancer and sepsis. Volition aims for cash flow neutrality by 2025 through non-dilutive funding, revenue growth, and cost reduction.
- Nexalin's CEO, Mark White, discusses the innovative Gen-3 HALO™ Clarity device for mental health treatments.
- Nexalin is positioned as a leader in a market expected to reach $537 billion by 2030.
- VolitionRX aims to achieve cash flow neutrality by 2025 through non-dilutive funding and cost reductions.
- VolitionRX has 85 patents granted and 131 pending, indicating a strong intellectual property portfolio.
- Volition anticipates accelerated revenue from the Nu.Q® Vet Cancer Test.
- No specific revenue figures or financial performance data for Nexalin were provided.
- The press release lacks detailed financial performance and specific growth metrics for Nexalin's products.
- No concrete figures or timelines were mentioned regarding the projected cash flow neutrality of VolitionRX.
- The success of Volition's strategy heavily depends on future milestone payments and non-dilutive funding, which carry inherent risks.
ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 15, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
Nexalin: https://www.redchip.com/assets/access/nxl_access
Volition: https://www.redchip.com/assets/access/vnrx_access
In an exclusive interview, Mark White, CEO of Nexalin, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. Nexalin stands at the forefront of the mental health treatment revolution with its cutting-edge, non-invasive neurostimulation technology. By focusing on deep brain stimulation, Nexalin's devices, particularly the advanced Gen-3 HALO™ Clarity, offer a groundbreaking alternative to traditional pharmacological treatments. This technology has shown clinically meaningful improvements in treating conditions such as insomnia, PTSD, and traumatic brain injuries-conditions that affect millions but have limited effective treatments-positioning Nexalin as an emerging leader in a market poised for substantial growth, projected to reach
Cameron Reynolds, President and CEO of Volition, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Volition employs an innovative approach to diagnostics through epigenetic markers, targeting significant global health challenges such as cancer and sepsis. Leveraging a robust intellectual property portfolio with 85 patents granted and 131 pending, Volition develops simple, low-cost blood tests adaptable to various diagnostic workflows. The company aims to achieve cash flow neutrality by 2025 through non-dilutive funding, revenue growth, milestone payments from out-licensing, and cost reduction measures targeting
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin's products are believed to be non-invasive and undetectable to the human body and developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device was recently approved in Oman and China. Additional information about the Company is available at: https://nexalin.com.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 32 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
info@redchip.com
--END--
SOURCE: RedChip
View the original press release on accesswire.com
FAQ
When will Nexalin Technology and VolitionRX interviews air on Bloomberg TV?
What technology does Nexalin Technology (NXL) focus on?
Which conditions does Nexalin's Gen-3 HALO™ Clarity device target?
What is VolitionRX's approach to diagnostics?
What financial goal does VolitionRX aim to achieve by 2025?
What revenue growth strategy is VolitionRX implementing?
